Your Directors are pleased to present the Thirty-sixth (36th) Annual Report together with Audited Annual Financial Statements
(including Audited Consolidated Financial Statements) of the Company for the Financial Year ended 31st March, 2025.

FINANCIAL HIGHLIGHTS (Rs. in Lakhs)

CONSOLIDATED FINANCIAL STATEMENTS

As required under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 [hereinafter referred to as "SEBI
(LODR) Reg, 2015"] and in accordance with the Indian Accounting Standard notified under the Companies (Indian Accounting
Standards) Rules, 2015, Consolidated Financial Statements of the Company and its subsidiaries form part of the Annual Report
and are reflected in the consolidated financial statements of the Company. These statements have been prepared on the basis
of audited financial statements received from the subsidiary companies as approved by their respective Boards.

DIVIDEND

The Board of Directors do not recommend any dividend for the financial year 2024-25.

In accordance with Regulation 43A of SEBI (LODR) Regulations, 2015, your company has adopted the Dividend Distribution
Policy with effect from June 22, 2021. The Policy lays down various parameters to be considered by the Board before the
declaration/recommendation of a dividend to the members of the Company. The Dividend Distribution Policy is available on
the website of the Company at https://www.sastasundarventures.com/Pdf/Dividend Distribution Policy.pdf

TRANSFER TO RESERVE

The Company has not transferred any amount to the General Reserve Account during the financial year ended 31st March,
2025.

STATE OF COMPANY'S AFFAIRS & OPERATIONS

During the financial year under review, your Company made significant progress on advancing its strategies. The Company is
committed to building a long-term business that offers a data-driven, digital supply chain for pharmaceuticals, diagnostics,
and wellness in India, catering to both B2B and B2C spaces. The Company has again relaunched Sastasundar App, B2C platform
for Pharmacy, Wellness and Diagnostic.

Our B2B platform, namely, Retailer Shakti is performing well and working as per plans. Further, Retailer Shakti Supply Chain
Private Limited has been amalgamated with the Sastasundar Healthbuddy Limited vide NCLT order dated 17th October, 2024.
Further, the management is actively working to understand and implement other strategies to enhance the growth of the
Company.

On a standalone basis, the revenue of your Company is Rs 40.40 Lakhs as against Rs 0.25 Lakhs during the previous year.
EBIDTA for the current year is Rs (60.37) Lakhs as compared to EBIDTA of Rs (76.90) Lakhs during the previous financial year. The
net loss for the year under review is Rs (71.37) Lakhs as against loss of Rs (89.29) Lakhs in the previous year.

On a consolidated basis, the revenue of your Company stood at Rs 1,11,095.46 Lakhs as against Rs 1,37,570.93 Lakhs during
the previous year. The EBIDTA for the current year is Rs 381.41 Lakhs as compared to EBIDTA of Rs. 6,582.59 Lakhs during the
previous financial year. The net loss for the year under review is Rs (13,354.30) Lakhs as against profit of Rs 585.26 Lakhs in the
previous year.

SCHEME OF AMALGAMATION OF MATERIAL SUBSIDIARY COMPANIES

The Scheme of Amalgamation amongst Retailer Shakti Supply Chain Private Limited ("Transferor Company"), step down
subsidiary company with Sastasundar Healthbuddy Limited ("Transferee Company"), subsidiary company and their respective
shareholders and creditors, ("Scheme"), under Sections 230 to 232 of the Companies Act, 2013 was approved by the Board in
the previous financial year. During the current year, the said Scheme has been sanctioned by the Hon'ble National Company
Law Tribunal, Kolkata Bench (NCLT) vide order dated 17th October, 2024. The order copy has been filed with the Registrar of
Companies, West Bengal and the Transferor Company (i.e., Retailer Shakti Supply Chain Private Limited, a material subsidiary
company) stands amalgamated.

DEPOSITS

During the year under review, the Company has neither accepted nor renewed any deposits from the public within the
meaning of Section 73 of the Companies Act, 2013, read with Companies (Acceptance of Deposits) Rules, 2014.

SHARE CAPITAL

The paid-up Equity share capital of the Company as at 31st March, 2025, stood at Rs. 31.81 crores, divided into 31810500
equity shares of face value of Rs. 10 each. There has been no change in the Authorised Paid-up Share Capital of the Company
during the year under review.

A) Issue of equity shares with differential rights: The Company did not issue equity shares with differential voting rights
during the financial year 2024-25.

B) Issue of sweat equity shares: The Company did not issue sweat equity shares during the financial year 2024-25.

C) Issue of employee stock options: The Company did not issue stock options during the financial year 2024-25.

D) Provision of money by the Company for purchase of its own shares by employees or by trustees for the benefit of
employees: The Company does not have a scheme for the purchase of its own shares by employees or by trustees for the
benefit of employees.

CHANGE IN NATURE OF BUSINESS, IF ANY

There has been no change in the nature of business of the Company during the financial year ended 31st March, 2025.
LOANS, GUARANTEES, AND INVESTMENTS

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are
given in the Note No. 5 to the Financial Statements.

MATERIAL CHANGES AND COMMITMENTS

No material changes and commitments affecting the financial position of your Company have occurred between the end of
the financial year of the Company to which the financial statements relates and the date of this report.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATOR/COURTS/TRIBUNALS IMPACTING THE GOING
CONCERN STATUS AND THE COMPANY'S OPERATIONS IN THE FUTURE

There were no significant and material orders passed by the Regulators or Courts, or Tribunals during the year impacting the
going concern status and the operations of the Company in the future.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

Your Company's Internal Control Systems are commensurate with the nature, size, and complexity of its business and ensure
proper safeguarding of assets, maintaining proper accounting records, and providing reliable financial information.

The Audit Committee have laid down internal financial controls to be followed by the Company and such policies and
procedures have been adopted by the Company for ensuring the orderly and efficient conduct of its business, including
adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the
accuracy and completeness of the accounting records and the timely preparation of reliable financial information.

An external independent firm carries out the internal audit of the Company operations and reports to the Audit Committee
on a regular basis. Internal Audit provides assurance on the functioning and quality of internal controls, along with adequacy
and effectiveness through periodic reporting.

However, the statutory auditors of the material subsidiary company, Sastasundar Healthbuddy Limited in their independent
auditor's Report have mentioned that the company did not have an appropriate internal control system for reconciliation
of receivables from vendors (logistic partners) which could potentially results in non-recovery/material misstatement of
receivables. Report on the Internal Financial Control under Section 143(3)(i) of the Companies Act, 2013 is attached as annexure
to the Independent Auditors Report of the Consolidated Financial Statement for the FY 2024-25 which is part of the report.

SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANIES:

As on March 31, 2025 the Company has nine subsidiaries (both direct and step down).

During the financial year, Sastasundar Healthbuddy Limited (SHBL), a material subsidiary company, has incorporated a wholly
owned subsidiary company, namely "Sastasundar Healthtech Private Limited" on 18th July, 2024, which is a step-down
subsidiary of Sastasundar Ventures Limited.

During the financial year, Retailer Shakti Supply Chain Private Limited, a material subsidiary company ceased to be a subsidiary
upon amalgamation with Sastasundar Healthbuddy Limited upon sanction of the Scheme by the Hon'ble National Company
Law Tribunal, Kolkata Bench (NCLT) vide order dated 17th October, 2024.

During the financial year, Sastasundar Healthbuddy Limited ("SHBL"), a material subsidiary of the Company, has, inter-alia,
entered into a Share Purchase Agreement ("SPA") dated 28th October, 2024 with Flipkart Health Private Limited, Singapore
(Purchaser), Flipkart Health Limited (Associate Company), Mr. B. L. Mittal (Founder) and Mr. Ravi Kant Sharma (Founder) for
sale of its entire stake, including both Equity Shares and Preference Shares held in Flipkart Health Limited to Flipkart Health
Private Limited, Singapore. Consequent to the above-mentioned proposed transaction, Flipkart Health Limited ceased to be
an Associate of the Company.

During the financial year, Sastasundar Healthbuddy Limited, subsidiary of the Company has entered into an agreement dated
14th February, 2025 for sale of its entire stake in Happymate Foods Limited. The aforesaid transaction for sale of stake of
Happymate Foods Limited was completed on 30th May, 2025. Consequent to the completion of this transaction, Happymate
Foods Limited ceased to be wholly owned subsidiary of Sastasundar Healthbuddy Limited and step-down subsidiary of the
Company.

In accordance with Section 129(3) of the Companies Act, 2013, the Company has prepared consolidated financial statements
of the Company and all its subsidiaries form part of the Annual Report. Further, a statement containing the salient features of
the financial statements of each of the subsidiaries in the prescribed format Form AOC-1, forms part of the Annual Report. The
annual accounts of the subsidiary companies will be made available to the shareholders on request and will also be kept for
inspection by the shareholders at the registered office of your Company.

Further, as per section 136 of the Companies Act, 2013, the audited financial statements, including the consolidated financial
statements and related information of the Company, are available at our website at www.sastasundarventures.com.

A Policy has been formulated for determining the Material Subsidiaries of the Company pursuant to Regulation 46 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 [hereinafter referred to as "SEBI (LODR) Reg,
2015"]. The said Policy has been posted on the Company's website at http://www.sastasundarventures.com/Pdf/SVL
PolicvforDeterminationofMaterialSubsidiarv.pdf

As per the provisions of Regulation 16(1)(c) of the SEBI (LODR) Regulations, 2015, the Company has one material unlisted
subsidiary, i.e., Sastasundar Healthbuddy Limited.

The Company does not have any Joint Venture Company and Associate Company.

BOARD OF DIRECTORS:

a) Directors and Key Managerial Personnel

As per the provision of the Companies Act, 2013, Mr. Ravi Kant Sharma (DIN: 00364066) retires by rotation at the ensuing Annual
General Meeting and being eligible, offers himself for re-appointment. Your Directors recommended the re-appointment of
Mr. Ravi Kant Sharma as Director.

The Board of Directors of the Company on 30th May, 2025 on the recommendation of the Nomination and Remuneration
Committee, re-appointed Mrs. Rupanjana De (DIN - 01560140) to hold office for a second term of five consecutive years i.e.
from 15th September, 2025, subject to the approval of the shareholders of the Company.

None of the Directors of the Company are disqualified for being appointed as a Director, as specified in section 164(2) of the
Companies Act, 2013, and Rule 14(1) of the Companies (Appointment and Qualification of Directors) Rules, 2014. Further,
in the opinion of the Board, the Independent Directors also possess the attributes of integrity, expertise and experience as
required to be disclosed under Rule 8(5)(iiia) of the Companies (Accounts) Rules, 2014.

The details of the Director being recommended for reappointment as required under the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 are contained in the accompanying Notice convening the ensuing Annual
General Meeting of the Company. Appropriate Resolution(s) seeking your approval to the re-appointment of Director are also
included in the Notice.

During the year under review, Mr. Lokesh Agarwal was appointed as Chief Financial Officer and Key Managerial Personnel of
the Company with effect from 15th February 2025 in place of Mrs. Manisha Sethia who has resigned as Chief Financial Officer
and Key Managerial Personnel with effect from closure of 14th February 2025.

Pursuant to Section 203 of the Companies Act, the Key Managerial Personnel of the Company are Mr. Banwari Lal Mittal,
Managing Director, Mr. Lokesh Agarwal, Chief Financial Officer, and Mr. Pratap Singh, Company Secretary.

None of the Director of the Company receives any commission from the Company. Mr. Banwari Lal Mittal, Managing Director
of the Company is also the Managing Director and CEO of Sastasundar Healthbuddy Limited (SHBL), the subsidiary company
and receives remuneration from SHBL. Mr. Lokesh Agarwal, Chief Financial Officer (CFO) of the Company is also the CFO of the
subsidiary company, SHBL and receives remuneration from SHBL.

b) Declaration by the Independent Director(s)

All the Independent Directors have furnished the requisite declarations that they meet the independence criteria as laid
down under section 149(6) of the Companies Act, 2013 read with the rules made thereunder and Regulation 16(1)(b) of the
SEBI (LODR) Reg, 2015. Further, the Board of Directors has taken on record the declaration and confirmation submitted by the
Independent Director under regulation 25(8) after assessing its veracity. The Independent Directors have also submitted a
declaration confirming that they have registered their names in the databank of Independent Directors as being maintained
by the Indian Institute of Corporate Affairs (IICA) in terms of Rule 6 of the Companies (Appointment and Qualification of
Directors) Rules, 2014. The Independent Directors have complied with the code for Independent Director as prescribed under
Schedule IV of the Companies Act, 2013.

c) Familiarization Programme undertaken for Independent Director

In terms of Regulation 25(7) of the SEBI (LODR) Reg, 2015, your Company is required to conduct Familiarisation Programme
for Independent Directors to familiarise them about your Company, including the nature of Industry in which your company
operates, business model, responsibilities of the Independent Directors, etc. Further, pursuant to Regulation 46 of the SEBI
(LODR) Reg, 2015, your Company is required to disseminate on its website, details of familiarization programmes imparted to
the IDs, including the details of the same. During the year, the Company has organised one familiarisation Programme of the
Independent Directors. The details of the familiarisation programme of Independent Directors are provided in the Corporate
Governance Report. The link to the details of familiarization programmes imparted to the Independent Directors is http://
www.sastasundarventures.com/Pdf/FamiliarizationProgrammeForIndependentDirector.pdf

d) Board Evaluation

The Nomination and Remuneration Committee of the Company has formulated and laid down criteria for Performance
evaluation of the Board (including Committees) and every director (including Independent Directors) pursuant to the
provisions of Section 134, Section 149 read with the code of Independent Director (Schedule IV) and Section 178 of the
Companies Act, 2013 read with Rules framed thereunder and Regulation 19(4) read with Part D of Schedule II of SEBI (LODR)
Reg, 2015.

For annual evaluation of the Board as a whole, its Committee(s) and Individual Directors, including the Chairman of the
Board, the Company has formulated a questionnaire to assist in the evaluation of the performance. The manner in which the
evaluation has been carried out has been explained in the Corporate Governance Report.

During the year under review, the Independent Directors of the Company reviewed the performance of Non-independent
Directors, the board as a whole, and the chairperson of the Company, taking into account the views of executive and non¬
executive directors.

e) Remuneration Policy

The Board has on the recommendation of the Nomination & Remuneration Committee, adopted the Remuneration Policy,
which inter alia includes policy for selection and appointment of Directors, Key Managerial Personnel, Senior Management
Personnel and their remuneration. The remuneration policy of the Company aims to attract, retain, and motivate qualified
people at the Executive and at the Board levels. The remuneration policy seeks to employ people who not only fulfill the
eligibility criteria but also have the attributes needed to fit into the corporate culture of the Company. The salient features of
the Policy have been disclosed in the Corporate Governance Report, which forms part of this Annual Report. The said policy is
available at the weblink: https://sastasundarventures.com/Pdf/SVL Remuneration policy.pdf.

MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEE

a) Board of Directors

The Board meets at regular intervals to discuss and decide on business policy and strategy apart from other Board business.
However, in case of special and urgent business need, the Board's approval is taken by passing resolutions through circulation,
as permitted by law, which are confirmed in the subsequent Board meeting. During the year under review, four Board Meetings

were convened and held on 30th May, 2024, 29th July, 2024, 14th November, 2024 and 14th February, 2025 the details of
which are given in the Corporate Governance Report. The meetings were held in compliance with the various provisions of
the Act/ SEBI (LODR) Reg, 2015.

b) Audit Committee

The composition, number of meetings held and attended and terms of reference of the Audit Committee has been furnished
in the Corporate Governance Report forming a part of this Annual Report. There has been no instance where the Board has
not accepted the recommendations of the Audit Committee.

c) Nomination and Remuneration Committee

The composition, number of meetings held and attended and terms of reference of the Nomination and Remuneration
Committee has been furnished in the Corporate Governance Report forming a part of this Annual Report.

d) Stakeholders Relationship Committee

The composition, number of meetings held and attended and terms of reference of the Stakeholders Relationship Committee
has been furnished in the Corporate Governance Report forming a part of this Annual Report.

e) Risk Management Committee

The composition, number of meetings held and attended and terms of reference of the Risk Management Committee has
been furnished in the Corporate Governance Report forming a part of this Annual Report.

f) Investment Committee

The composition, number of meetings held and attended and terms of reference of the Investment Committee has been
furnished in the Corporate Governance Report forming a part of this Annual Report.

g) Restructuring Committee

The composition, number of meetings held and attended and terms of reference of the Restructuring Committee has been
furnished in the Corporate Governance Report forming a part of this Annual Report.

h) Separate Meeting of Independent Directors

The Independent Directors met on 14th November, 2024 and 24th March, 2025 without the attendance of Non-Independent
Directors and members of the Management. The Independent Directors at its meeting held on 14th November, 2024 and
24th March, 2025, reviewed the performance of Non-Independent Directors and the Board as a whole, the performance of the
Chairman of the Company, taking into account the views of Executive Directors and Non-Executive Directors and assessed the
quality, quantity and timeliness of flow of information between the Company Management and the Board that is necessary
for the Board to effectively and reasonably perform their duties.

AUDITORS

(a) Statutory Auditors

M/s. JKVS & Co., Chartered Accountants (Firm Registration Number: 318086E), the Statutory Auditors of the Company have
been appointed as Statutory Auditors of the Company by the Members of the Company from the conclusion of 33rd Annual
General Meeting held on 29th September, 2022 till the conclusion of 38th Annual General Meeting of the Company to be held
in the year 2027.

M/s. JKVS & Co., Chartered Accountants, the Statutory Auditors have submitted their Independent Auditor Report for the
financial year ended 31st March, 2025 and they have made no qualification, reservation, observation or adverse remarks or
disclaimer in their Standalone and Consolidated Audit Report.

(b) Secretarial Auditor

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with corresponding Rules framed thereunder, M/s
MKB & Associates, Practicing Company Secretaries (Firm Reg No: P2010WB042700) were appointed as the Secretarial Auditors
of the Company to carry out the secretarial audit of the Company for FY 2024-25.

Further, in terms of Section 204 of the Act and Regulation 24A of the SEBI (LODR) Reg, 2015, the Board of Directors has, on
the recommendation of the Audit Committee, approved the appointment of M/s. MKB & Associates, Practicing Company
Secretaries, as the Secretarial Auditors of the Company, to hold office for a term of five (5) consecutive years with effect from
FY 2025-26 to FY 2029-30, subject to the approval of the members at the ensuing Annual General Meeting.

Annual Secretarial Audit Report

In terms of Section 204 of the Companies Act, 2013 and Regulation 24A of the SEBI (LODR) Reg, 2015, a Secretarial Audit
Report for the financial year ended 31st March, 2025 given by the Secretarial Auditors in Form No. MR-3 is annexed with this
Report as "Annexure- I". There has been no qualification, reservation, adverse remark or disclaimer given by the Secretarial
Auditors in their Report.

As required under Regulation 24A of the SEBI (LODR) Reg, 2015, Secretarial Audit Report in Form No. MR-3 of Sastasundar
Healthbuddy Limited, material unlisted subsidiary of the Company is also annexed herewith and marked as "Annexure- II".

FRAUD REPORTING

During the year under review, there was no fraud reported by the Auditors of the Company under section 143(12) of the
Companies Act, 2013 to the Board of Directors pertaining to the financial year 2024-25.

RELATED PARTY TRANSACTIONS

During the financial year 2024-25, your Company has entered into transactions with related parties as defined under Section
2(76) of the Companies Act, 2013 read with Companies (Specification of Definitions Details) Rules, 2014, which were in the
ordinary course of business and on arms' length basis and in accordance with the provisions of the Companies Act, 2013, Rules
issued thereunder and SEBI (LODR) Reg, 2015. Thus, the disclosure in Form AOC-2 in terms of Section 134 of the Companies
Act, 2013 is not required. However, your attention is drawn to the Related Party disclosure in Note No. 25 of the Standalone
Financial Statements.

During the financial year 2024-25, there were no materially significant related party transactions entered into by the Company,
which may have a potential conflict with the interest of the Company at large. There were no pecuniary relationships or
transactions entered into by any Independent Director with the Company during the year under review.

At the Annual General Meeting held on 29th September, 2022 the Company has taken approval from the members for
Material Related Party Transaction(s) between Sastasundar Healthbuddy Limited (SHBL), subsidiary of Sastasundar Ventures
Limited and Retailer Shakti Supply Chain Private Limited (RSSCPL), step down subsidiary of Sastasundar Ventures Limited for
an aggregate value of upto Rs. 300 crore for each financial year, subject to such contract(s)/ arrangement(s)/ transaction(s)
being carried out at arm's length and in the ordinary course of business of SHBL and RSSCPL. Retailer Shakti Supply Chain
Private Limited (RSSCPL), a step-down subsidiary of Sastasundar Ventures Limited, has been amalgamated with Sastasundar
Healthbuddy Limited (SHBL), a subsidiary of Sastasundar Ventures Limited, vide NCLT's order dated 17.10.2024.

All Related Party Transactions are placed before the Audit Committee and also before the Board for approval. Omnibus
approval was obtained on a yearly basis for transactions that were of repetitive nature. Transactions entered into pursuant to
omnibus approval of all the Related Party Transactions are placed before the Audit Committee and the Board for review and
approval on a quarterly basis.

The Company has formulated a policy on related party transactions for the purpose of identification and monitoring of such
transactions. The said policy on related party transactions as approved by the Board is posted at the Company's website at the
weblink https://www.sastasundarventures.com/Pdf/SVL Related Party Transaction Policy.pdf

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information relating to conservation of energy, technology absorption, foreign exchange earnings and outgo as per
section 134(3)(m) of the Companies Act, 2013, read with Rule 8 of the Companies (Accounts) Rules, 2014 is annexed herewith
as "Annexure - III".

PARTICULARS OF EMPLOYEES & RELATED DISCLOSURES

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Act read with Rule 5(1) of
the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this Report as "Annexure
- IV" and form part of the Report.

ANNUAL RETURN

Pursuant to the provisions of Section 134(3)(a) and Section 92(3) of the Act, as amended, read with Rule 12 of the Companies
(Management and Administration) Rules, 2014, the Annual Return of the Company for the Financial Year ended 31st March, 2025
is available on the website of the Company at https://www.sastasundarventures.com/Pdf/Draft Annual Return 31.03.2025.
pdf

VIGIL MECHANISM / WHISTLE BLOWER POLICY

The Company has adopted a Whistle Blower Policy to provide a formal mechanism to the Directors and Employees to report
their concern about unethical behaviour, actual or suspected fraud, or violation of the Company's Code of Conduct or ethics
policy. The policy provides for adequate safeguards against victimization of employees who avail of the mechanism and also
provides for direct access to the Chairman of the Audit Committee. The details of the Whistle Blower Policy is explained in the
Corporate Governance Report and also posted on the website of the Company at the weblink http://www.sastasundarventures.
com/Pdf/SVL whistle blower policy.pdf

During the year under review, no complaints have been received/reported.

CORPORATE SOCIAL RESPONSIBILITY

The provisions relating to the Corporate Social Responsibility ("CSR") are not applicable to the Company.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT

The Securities and Exchange Board of India (SEBI) has mandated India's top 1,000 listed entities based on market capitalization
on the BSE and NSE as on March 31, 2022 to submit a 'Business Responsibility and Sustainability Report' (BRSR) along with
their Annual Report from the financial year 2022-23. This report is required to be in line with the 'National Voluntary Guidelines
on Social, Environmental and Economic Responsibilities of Business' (NVGs) as released by the Ministry of Corporate Affairs
(MCA) in July, 2011 and the amendment to SEBI (LODR) Reg, 2015 in May 2021. As per Regulation 34(2)(f) of SEBI (LODR) Reg
2015, BRSR is a report on the nine principles of the National Voluntary Guidelines on social, environmental and economic
responsibilities of business as framed by the MCA, is annexed herewith for the FY 2024-25 as "Annexure- V" and forms a part
of this Report.

POLICY ON PREVENTION OF INSIDER TRADING

Your Company has adopted a Code for Prevention of Insider Trading with a view to regulating trading in equity shares of
the Company by the Directors and designated employees of the Company. The Code of Conduct is available on the website
of the Company at www.sastasundarventures.com. The Code requires preclearance for dealing in the Company's shares
and prohibits the purchase or sale of shares in your company by the Directors and designated employees, while they are in
possession of unpublished price sensitive information and also during the period when the Trading Window remains closed.

CORPORATE GOVERNANCE REPORT AND MANAGEMENT DISCUSSION ANALYSIS REPORT

The Company is committed to maintaining the highest standards of corporate governance and adhering to the corporate
governance requirements as set out by SEBI. The Company has also implemented several best corporate governance practices.
The report on Corporate Governance and Management Discussion & Analysis Report, as stipulated under Schedule V of the
SEBI (LODR) Regulations, 2015, forms an integral part of this report.

PRACTICING COMPANY SECRETARIES' CERTIFICATE ON CORPORATE GOVERNANCE

In Compliance with the provisions of Regulation 34 of the SEBI (LODR) Reg, 2015 read with Schedule V of the said Regulations,
the Corporate Governance Certificate issued by the Practicing Company Secretaries, M/s MKB & Associates, Company
Secretaries regarding compliance with the conditions of Corporate Governance as stipulated is annexed to this report.

Your Company has taken adequate steps for strict compliance with the Corporate Governance guidelines, as amended from
time to time.

COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND GENERAL MEETINGS

The Company has complied with Secretarial Standard on Meetings of the Board of Directors (SS-1) and General Meetings (SS-
2) issued by the Institute of Company Secretaries of India during the year under review.

LISTING WITH STOCK EXCHANGES

Your Company is listed with BSE Ltd. and National Stock Exchange of India Ltd., and the Company has paid the Listing Fees to
both exchanges on time.

CHIEF EXECUTIVE OFFICER (CEO) / CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

As required under Regulation 17(8) of the SEBI (LODR) Reg, 2015, the CEO/CFO certification has been submitted to the Board
and a copy thereof is contained elsewhere in this Annual Report.

RISK MANAGEMENT

Your Company's risk management strategy strives to balance the trade-off between risk and return and ensure optimal risk-
adjusted return on capital, and entails independent identification, measurement, and management of risks across the various
businesses of your Company.

The Company has formulated a Risk Assessment & Management Policy which identify, evaluate business risks and opportunities.
The risk management system of the Company is reviewed by the Audit Committee and the Board of Directors on a regular
basis. During the year, no major risks were noticed, which may threaten the existence of the company.

The Company has duly constituted risk management committee, the details of the same are covered in the Corporate
Governance Report forming part of the Board's Report.

DIRECTORS' RESPONSIBILITY STATEMENT

The Directors acknowledges the responsibility for ensuring compliances with the provisions of section 134(3)(c) read with
section 134(5) of the Companies Act, 2013 and provisions of the SEBI (LODR) Reg, 2015 and in the preparation of the annual
accounts for the year ended 31st March, 2025 states that —

(a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with a proper
explanation relating to material departures;

(b) they have selected such accounting policies and applied them consistently and made judgments and estimates that are
reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial
year and of the profit and loss of the company for that year;

(c) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with
the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other
irregularities;

(d) the annual accounts have been prepared on a going concern basis;

(e) they have laid down internal financial controls to be followed by the Company and that such internal financial controls
are adequate and were operating effectively; and

(f) proper systems had been devised to ensure compliance with the provisions of all applicable laws, and that such systems
were adequate and operating effectively.

OTHER DISCLOSURES

Your Directors state that:

1. No proceedings are pending against the Company under the Insolvency and Bankruptcy Code, 2016.

2. The Company serviced all the debts & financial commitments as and when they became due and no settlements were
entered into with the bankers.

3. The company is not required to maintain cost records.

4. The Company is in compliance with the applicable provisions relating to the Maternity Benefit Act, 1961.

DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL)
ACT, 2013

Your Company is committed to provide a safe and secure environment to its women employees across its functions, as they
are considered an integral and important part of the Organisation. Your company has in place a policy for prevention of
Sexual Harassment in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition
& Redressal) Act, 2013.

In terms of provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and
Rules framed thereunder, your Company has duly adopted a Policy and has also complied with the provisions relating to the
constitution of the Internal Complaints Committee (ICC). There was no case of sexual harassment reported during the year
under review, as stated below:

HUMAN RESOURCES

Our employees are our core resource, and the Company has continuously evolved policies to strengthen its employee value
proposition. Your Company was able to attract and retain the best talent in the market, and the same can be felt in the past
growth of SastaSundar Group. The Company is constantly working on providing the best working environment to its Human
Resources with a view to inculcate leadership, autonomy and towards this objective, your company spends large efforts on
training. Your Company shall always place all necessary emphasis on the continuous development of its Human Resources.
The belief "great people create great organization" has been at the core of the Company's approach to its people.

ACKNOWLEDGEMENTS

Your Directors take this opportunity to thank the Regulatory and Government Authorities, Bankers, Business Associates,
Shareholders, and the Customers of the Company for their continued support to the Company. The Directors express their
deep sense of appreciation towards all the employees and staff of the Company and wish the management all the best for
achieving greater heights in the future.

For and on behalf of the Board
Banwari Lal Mittal

Date: August 12, 2025 Chairman & Managing Director

Place: Kolkata DIN: 00365809